MNMD vs. TLRY, CRON, USNA, CGC, BTMD, ACB, CDXC, MDWD, FTLF, and BGXX
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Mind Medicine (MindMed) (NASDAQ:MNMD) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 9.4% of Tilray shares are owned by institutional investors. 2.3% of Mind Medicine (MindMed) shares are owned by insiders. Comparatively, 0.7% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Mind Medicine (MindMed) has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500.
In the previous week, Mind Medicine (MindMed) had 1 more articles in the media than Tilray. MarketBeat recorded 13 mentions for Mind Medicine (MindMed) and 12 mentions for Tilray. Mind Medicine (MindMed)'s average media sentiment score of 0.46 beat Tilray's score of 0.37 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media.
Tilray received 408 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 90.70% of users gave Mind Medicine (MindMed) an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Mind Medicine (MindMed) presently has a consensus target price of $19.00, indicating a potential upside of 115.91%. Tilray has a consensus target price of $2.71, indicating a potential upside of 50.46%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, equities analysts plainly believe Mind Medicine (MindMed) is more favorable than Tilray.
Mind Medicine (MindMed) has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed) has a net margin of 0.00% compared to Tilray's net margin of -43.98%. Tilray's return on equity of -2.68% beat Mind Medicine (MindMed)'s return on equity.
Summary
Mind Medicine (MindMed) beats Tilray on 13 of the 18 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
